Today, popular GLP-1 medicines used for weight loss and diabetes generally require patients to take

New approach proposes an alternative to repeated injections HOUSTON, Oct. 7, 2026 /PRNewswire/ -- Fi

FibroBiologics files a U.S. patent application for engineered cell technology designed to supply con

Gainers Anbio Biotechnology (NASDAQ:NNNN) stock moved upwards by 16.9% to $6.49 during Friday's

FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-

Newly Granted Patent Covers Methods of Augmenting the Regenerative Efficacy of Fibroblasts Using Pla

Gainers Onconetix (NASDAQ:ONCO) stock increased by 10.3% to $1.14 during Friday's after-market

FibroBiologics, Inc. (FBLG) Discusses Strategy and Clinical Progress in Fibroblast-Based Cell Therap

Gainers Decoy Therapeutics (NASDAQ:DCOY) shares rose 84.0% to $4.71 during Tuesday's pre-market

FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-s

HOUSTON, Sept. 17, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the

Newly Issued Patent Covers Topical Administration of 3D Spheroid Fibroblasts and Fibroblast-Derived

Newly Issued Patent Covers Topical Administration of 3D Spheroid Fibroblasts and Fibroblast-Derived

FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-

Newly Issued Patent Covers Methods of Promoting Disc Regeneration Using Components Derived from Stim

FibroBiologics (NASDAQ:FBLG), a clinical-stage biotechnology company, has released and shipped the t

FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-s

HOUSTON, Aug. 27, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the

FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-

HOUSTON, Aug. 26, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the

Legendary Sports Agent, Attorney, and Longtime Advocate for Human Longevity and Brain Health Joins B

Patent covers the use of cannabidiol in combination with fibroblast-based cell therapy to treat dege

FibroBiologics Inc. (NASDAQ:FBLG), a clinical-stage biotechnology company, on Tuesday revealed a sig

FibroBiologics reports promising preclinical results for a novel joint repair therapy, offering a fa

FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology compa

Animal trials show cartilage repair within four weeks following a single injection of chondrocyte sp

Patent has potential for applications beyond diabetes, including other cell and tissue transplantati

Patent has potential for applications beyond diabetes, including other cell and tissue transplantati

FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-

Granted claims cover Sox9-based conversion of fibroblasts into cartilage-producing cells, supporting

Top Wall Street analysts changed outlook on top names. Complete view of analyst rating changes, incl

HC Wainwright & Co. analyst Matthew Caufield maintains FibroBiologics (NASDAQ:FBLG) with a Bu

FibroBiologics, Inc. - Common Stock (NASDAQ:FBLG) reported quarterly losses of $(0.66) per share whi

- First patients dosed in phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers - On t

Microbiologist, Retired NASA Astronaut, and Founding Director of the University of Pittsburgh Trived

Company expects existing supply will suffice to complete clinical trial and lead to cost savingsHOUS

Company expects existing supply will suffice to complete clinical trial and lead to cost savings HOU

HOUSTON, June 30, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a cli

$3.0 million upfront with up to approximately $6.0 million of potential additional gross proceeds up

FibroBiologics, Inc. (NASDAQ: FBLG) ("FibroBiologics" or the "Company"), a clinical-

FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology compa

FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology compa

FibroBiologics Inc. (NASDAQ: FBLG) reports enrolling first patients in its Phase 1/2 trial for CYWC6

Psoriasis is a chronic inflammatory skin disease driven by dysregulated innate and adaptive immunity

The application covers oral delivery systems designed to protect fibroblast-based therapeutics throu

FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology compan

FibroBiologics releases CYWC628 batch for DFU trial, clears cGMP checks, prepares enrollment; interi

FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology compan

HC Wainwright & Co. analyst Matthew Caufield maintains FibroBiologics (NASDAQ:FBLG) with a Bu